Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges

Velcheti, Vamsidhar; Pennell, Nathan A.

doi:10.21037/atm.2017.08.24

Cited by 6 publications

(5 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different types of dry etching process exist, with varying degrees of isotropy. For example, oxygen plasma etching is frequently used in microfabrication processes to clean organic contaminants from surfaces, increase the surface energy to promote adhesion, or to alter the size of patterned structures . However, the process is highly isotropic, limiting its efficacy for fabricating high‐aspect‐ratio nanostructures.…”

Section: Fabrication Techniquesmentioning

confidence: 99%

High‐Aspect‐Ratio Nanostructured Surfaces as Biological Metamaterials

et al. 2020

View full text Add to dashboard Cite

Materials patterned with high‐aspect‐ratio nanostructures have features on similar length scales to cellular components. These surfaces are an extreme topography on the cellular level and have become useful tools for perturbing and sensing the cellular environment. Motivation comes from the ability of high‐aspect‐ratio nanostructures to deliver cargoes into cells and tissues, access the intracellular environment, and control cell behavior. These structures directly perturb cells' ability to sense and respond to external forces, influencing cell fate, and enabling new mechanistic studies. Through careful design of their nanoscale structure, these systems act as biological metamaterials, eliciting unusual biological responses. While predominantly used to interface eukaryotic cells, there is growing interest in nonanimal and prokaryotic cell interfacing. Both experimental and theoretical studies have attempted to develop a mechanistic understanding for the observed behaviors, predominantly focusing on the cell–nanostructure interface. This review considers how high‐aspect‐ratio nanostructured surfaces are used to both stimulate and sense biological systems.

show abstract

Section: Fabrication Techniquesmentioning

confidence: 99%

High‐Aspect‐Ratio Nanostructured Surfaces as Biological Metamaterials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, the accuracy of these diagnostic tools is greatly affected by the experience of operators and observers (1). Therefore, it is of great value to develop non-invasive and low-cost tools to detect lung cancer, such as blood tumor markers (2).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of human epididymis secretory protein 4 for lung cancer: a systematic review and meta-analysis

2019

J. Thorac. Dis

View full text Add to dashboard Cite

Background: Several studies have assessed the diagnostic accuracy of serum human epididymis secretory protein 4 (HE4) for lung cancer, but their results were heterogeneous. The aim of this study was to systematically review the available studies and pool their results using meta-analysis. Methods: PubMed, EMBASE and Web of Science databases were searched up to January 1, 2019 to identify studies investigating the diagnostic accuracy of HE4 for lung cancer. We assessed the quality of eligible studies with the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. The overall diagnostic sensitivity, specificity, positive and negative likelihood ratios were pooled using a bivariate model. Deeks's test was applied to detect the degree of publication bias. Results: A total of 16 studies with 18 cohorts (1,756 lung cancers and 1,446 controls) were included. HE4 had a pooled sensitivity of 0.65 (95% CI: 0.54-0.75), specificity of 0.88 (95% CI: 0.82-0.92), positive likelihood ration of 5.3 (95% CI: 3.7-7.6) and negative likelihood ratio of 0.40 (95% CI: 0.30-0.52). Patient selection bias and partial verification bias were the major design weaknesses of available studies. No publication bias was observed. Conclusions: HE4 has moderate diagnostic accuracy for lung cancer. Its result should be interpreted in parallel with clinical findings and the results of other conventional tests. Further studies are still needed to rigorously evaluate the diagnostic accuracy of HE4 for lung cancer.

show abstract

“…In addition, several advances have been made in ctDNA and circulating tumor cell (CTC)-based tests offering a potential alternative for detection of BRAF V600E mutation, however tissue based testing for BRAF is still considered the gold standard. 57 , 58 A joint guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology currently recommends inclusion of BRAF molecular testing as part of expanded testing panel but it did not recommend genetic testing of BRAF as a routine stand-alone assay. 59 …”

Section: Introductionmentioning

confidence: 99%

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

Khunger

Velcheti

2018

Ther Adv Respir Dis

Self Cite

View full text Add to dashboard Cite

Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within the BRAF kinase. BRAF-targeted therapies are effective in patients with melanoma and NSCLC harboring BRAF V600E mutation. In both melanoma and NSCLC, dual inhibition of both BRAF and the downstream mitogen-activated protein kinase (MEK) improves response rates compared with BRAF inhibition alone. BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation. Here, in this review, we outline the preclinical and clinical data for BRAF and MEK inhibitor combination treatment for NSCLC patients with BRAF V600E mutation.

show abstract

Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges

Cited by 6 publications

References 70 publications

High‐Aspect‐Ratio Nanostructured Surfaces as Biological Metamaterials

High‐Aspect‐Ratio Nanostructured Surfaces as Biological Metamaterials

Diagnostic accuracy of human epididymis secretory protein 4 for lung cancer: a systematic review and meta-analysis

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

Contact Info

Product

Resources

About